Document Detail

BAFF and selection of autoreactive B cells.
MedLine Citation:
PMID:  21752714     Owner:  NLM     Status:  MEDLINE    
B cell activating factor (BAFF) is a crucial survival factor for transitional and mature B cells, and is a promising therapeutic target for systemic lupus erythematosus (SLE). A BAFF inhibitor, belimumab, is the first new drug in 50 years to be approved for the treatment of SLE. However, the mechanism of action of this drug is not entirely clear. In this review we will focus on the role of the BAFF-APRIL signaling pathway in the selection of autoreactive B cells, and discuss whether altered selection is the mechanism for the therapeutic efficacy of BAFF inhibition in SLE.
Zheng Liu; Anne Davidson
Related Documents :
22130534 - Kaposi's sarcoma-associated herpesvirus latency-associated nuclear antigen and angiogen...
21857494 - A novel role for slit2/robo1 axis in modulating hiv-1 replication in t cells.
21901254 - Knockdown of ron inhibits ap-1 activity and induces apoptosis and cell cycle arrest thr...
22111844 - Revised guidelines for the diagnosis and management of hairy cell leukaemia and hairy c...
7840424 - Localization of diazepam-binding inhibitor and peripheral type benzodiazepine binding s...
21991364 - Inhibitory activity of ykl-40 in mammary epithelial cell differentiation and polarizati...
Publication Detail:
Type:  Journal Article; Review     Date:  2011-07-13
Journal Detail:
Title:  Trends in immunology     Volume:  32     ISSN:  1471-4981     ISO Abbreviation:  Trends Immunol.     Publication Date:  2011 Aug 
Date Detail:
Created Date:  2011-08-05     Completed Date:  2011-11-28     Revised Date:  2014-09-11    
Medline Journal Info:
Nlm Unique ID:  100966032     Medline TA:  Trends Immunol     Country:  England    
Other Details:
Languages:  eng     Pagination:  388-94     Citation Subset:  IM    
Copyright Information:
Copyright © 2011 Elsevier Ltd. All rights reserved.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antibodies, Monoclonal / pharmacology
Antibodies, Monoclonal, Humanized
Autoimmunity / drug effects
B-Cell Activating Factor / immunology*
B-Lymphocytes / drug effects,  immunology*
Clonal Selection, Antigen-Mediated* / drug effects
Lupus Erythematosus, Systemic / drug therapy,  immunology*
Signal Transduction / drug effects,  immunology
Tumor Necrosis Factor Ligand Superfamily Member 13 / immunology*
Grant Support
R01 AI083901/AI/NIAID NIH HHS; R01 AI083901-02/AI/NIAID NIH HHS; R01 AR049938/AR/NIAMS NIH HHS; R01 AR049938-05/AR/NIAMS NIH HHS
Reg. No./Substance:
0/Antibodies, Monoclonal; 0/Antibodies, Monoclonal, Humanized; 0/B-Cell Activating Factor; 0/TNFSF13B protein, human; 0/Tumor Necrosis Factor Ligand Superfamily Member 13; 73B0K5S26A/belimumab

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  ADAM17: a molecular switch to control inflammation and tissue regeneration.
Next Document:  Unifying concepts of MHC-dependent natural killer cell education.